| 2015-11-02 | Sale | Travere Therapeutics, Inc. TVTX | General Counsel | 100,000 0.2687% | $20.46 | $2.05M | -16.1% | |
| 2011-02-28 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 24,640 0.0453% | $6.83 | $168,207 | +8% | |
| 2010-03-01 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 24,980 0.0532% | $2.53 | $63,209 | +131.76% | |
| 2010-01-12 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 17,394 0.0374% | $2.52 | $43,882 | +121.43% | |
| 2009-03-30 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 24,234 0.0614% | $3.43 | $83,098 | -15.43% | |
| 2009-01-12 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 16,926 0.0447% | $3.25 | $54,984 | -1.26% | |
| 2008-02-12 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 15,326 0.0402% | $5.03 | $77,124 | -6.59% | |
| 2003-05-27 | Sale | Neurocrine Biosciences, Inc. NBIX | EVP and General Counsel | 25,000 0.0781% | $50.09 | $1.25M | +5.01% |